Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Base Pair BiotechnologiesBase Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Publication Number
US-9035034-B2
Publication Date
2015-05-19
Expiration Date
Abstract
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules. The present invention further relates to methods for generating, for example, functional biomolecules, particularly to functional nucleic acids, that bind with functional activity to another biomolecule, such as a receptor molecule. More than one or multiple targets as used herein may generally include different types of targets, and/or may also include a multitude of a singular type of targets at different conditions, such as, for example, temperature, pH, chemical environment, and/or any other appropriate conditions.
Core Innovation
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules and to methods for generating functional biomolecules that bind with functional activity to another biomolecule, such as a receptor molecule.
Aptamers are commonly identified by an in vitro method of selection sometimes referred to as Systematic Evolution of Ligands by EXponential enrichment or 'SELEX.' SELEX typically begins with a very large pool of randomized polynucleotides which is generally narrowed to one aptamer ligand per molecular target, and once multiple rounds (typically 10-15) of SELEX are completed, the nucleic acid sequences are identified by conventional cloning and sequencing.
Claims Coverage
This patent includes two inventive features extracted from two independent claims.
Nucleic acid ligand having at least 95% homology or identity to listed sequences
A ligand to a target molecule comprising a nucleic acid sequence having at least 95% homology or identity to a sequence selected from the group consisting of sequence IDs Seq40, Seq41, Seq42, Seq44, Seq45, Seq46, Seq47, Seq48, and Seq49.
Modified nucleic acid ligand having at least 95% homology or identity to listed sequences
A ligand to a target molecule comprising a modified nucleic acid sequence having at least 95% homology or identity to a sequence selected from the group consisting of sequence IDs Seq40, Seq41, Seq42, Seq44, Seq45, Seq46, Seq47, Seq48, and Seq49.
The independent claims cover ligands to target molecules defined by nucleic acid sequences or modified nucleic acid sequences with at least 95% homology or identity to specific sequence IDs (Seq40, Seq41, Seq42, Seq44, Seq45, Seq46, Seq47, Seq48, Seq49).
Stated Advantages
High-capacity, multiplexed identification procedures that may save time, expense, and physical space compared to single target identification processes.
Ability to identify and/or eliminate biomolecules that bind or have a tendency to bind to multiple targets.
Association of a given library member with a particular target via marking or tagging, preserving the particular sequence of the member while appending a locational identifying sequence.
Performing multiple rounds of selection in solution prior to final binding and marking/tagging on an array may be desirable for cost and ease compared to performing all rounds on complex target arrays.
Documented Applications
Aptamers and functional ligands used as sensors, therapeutic tools, to regulate cellular processes, and to guide drugs to their specific cellular target(s).
Use of aptamers as immobilized capture elements in a microarray format.
Generation of functional nucleic acid ligands against proteins, small organic molecules, cellular toxins, viruses, and heavy metal ions.
Application of peptide-display methods including phage display, mRNA display, and ribosome display to generate peptide binders that are tagged via associated nucleic acid sequences.
Use of histology sections or tissue/cell sections on slides as target sets for binding and subsequent identifier tagging.
Monitoring and controlling library diversity during selection using Cot analysis (Concentration×time) to measure annealing time of oligonucleotides as a measure of sequence diversity.
Interested in licensing this patent?